PHARMAXIS LTD PXS

PXS ASX
PXS
PHARMAXIS LTD ASX
 
No trades
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E

PXS Chart

Trade PXS with trusted brokers on TradingView Open account

Analyst rating

Valuation
Enterprise Value/EBITDA, TTM
Enterprise Value, FQ
Market Cap — Basic
Number of Employees
Number of Shareholders
Price/Earnings, TTM
Price/Revenue, TTM
Price/Book Ratio, FY
Price/Sales Ratio, FY
Balance Sheet
Current Ratio, FQ
Debt to Equity, FQ
Net Debt, FQ
Quick Ratio, FQ
Total Assets, FQ
Total Debt, FQ
Operating Metrics
Return on Assets, TTM
Return on Equity, TTM
Return on Invested Capital, TTM
Revenue per Employee, TTM
Price History
Average Volume (10 day)
Beta - 1 Year
Price - 52 Week High
Price - 52 Week Low
Dividends
Dividends Paid, FY
Dividends per Share, FY
Expected Annual Dividends
Dividends Yield
Margins
Net Margin, TTM
Gross Margin, TTM
Operating Margin, TTM
Pretax Margin, TTM
Income Statement
Basic EPS, Net Income
Earnings per Share, Basic, TTM
EBITDA, TTM
Gross Profit, FY
Last Annual EPS
Last Annual Revenue, FY
Net Income, FY
Total Revenue, FY
Free Cash Flow, TTM

Profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Pharmaxis Ltd. is a pharmaceutical research company, which engages in the development and commercialization of therapeutic products for chronic respiratory disorders, autoimmune diseases, and improved lung function test. It operates through the following segments: Mannitol Respiratory Business and New Drug Development. The Mannitol Respiratory Business segment covers the clinical development, manufacture, and sale of Bronchitol and Aridol globally. The New Drug Development segment encompasses the drug discovery and early stage clinical development of the group's new drug candidates. The company was founded by Brett Charlton and William B. Cowden on May 29, 1998 and is headquartered in Sydney, Australia.